Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Sensory-Evoked Cortical Gamma Oscillation

Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Who May Be Eligible (Plain English)

Who May Qualify: - Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011) - Fluent and literate in English language - Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research - Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results Who Should NOT Join This Trial: - Not fluent and literate in English - Severe dementia - Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities - Cardiac pacemakers or any other implants that may not be compatible with MRI - Cognitively impaired to the point the patient is unable to consent for themselves - Claustrophobic to the point that medication is required Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011) * Fluent and literate in English language * Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research * Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results Exclusion Criteria: * Not fluent and literate in English * Severe dementia * Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities * Cardiac pacemakers or any other implants that may not be compatible with MRI * Cognitively impaired to the point the patient is unable to consent for themselves * Claustrophobic to the point that medication is required

Treatments Being Tested

DEVICE

GammaSense Stimulation device

Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.

Locations (1)

University of Tennessee Medical Center
Knoxville, Tennessee, United States